Article Text

PDF
▼Omalizumab for severe asthma?

Abstract

Up to 5% of patients with asthma have severe disease1,2 (i.e. around 250,000 people in the UK3). This means their asthma remains uncontrolled despite optimal treatment with high-dose inhaled corticosteroid plus additional therapy or a regular oral corticosteroid,4 and with no other explanations such as poor adherence to therapy and other diagnoses such as vocal cord dysfunction. ▼Omalizumab (pronounced oh-ma-liz-oo-mab) (Xolair - Novartis) is a monoclonal antibody to IgE that is available in the UK as add-on therapy for people aged 12 years and over with severe persistent asthma that has an important allergic component. What benefits, if any, does omalizumab offer to such patients?

Statistics from Altmetric.com

  • Relevant BNF section: 3.4.2

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.